Sign in to continue:

Saturday, March 7th, 2026

Johnson Controls International PLC 8-K Filing Summary: Company Details, Securities, and XBRL Data (March 2026)




Johnson Controls International PLC 2026 AGM Results: Key Shareholder Updates

Johnson Controls International PLC Reports Results of 2026 Annual General Meeting

Johnson Controls International PLC (“the Company”) has released the official results of its Annual General Meeting (AGM) held on March 4, 2026. The meeting covered several key proposals that could have implications for investors, including the appointment of auditors, share buyback authority, executive compensation, and the Board’s authority to allot and issue shares. The results reflect significant shareholder engagement and the successful passage of all management proposals.

Key Highlights from the AGM

  • Strong Shareholder Turnout: Holders of 556,390,065 ordinary shares were represented in person or by proxy, constituting a quorum.
  • All Proposals Approved: All management proposals were approved by the requisite majorities.
  • Potential Share Price Sensitivity: Several proposals directly affect share capital structure, potential dilution, and capital allocation, which may be material for investors.

Detailed Voting Results and Impacts

1. Ratification of Independent Auditors

Proposal: Ratify PricewaterhouseCoopers LLP as the independent auditors.
Votes For: 543,530,855
Votes Against: 12,401,799
Abstain: 457,411
Status: Approved

This ensures continuity in the Company’s auditing and financial reporting. No significant change expected in financial oversight, but strong support signals investor trust in current governance.

2. Market Purchases of Company Shares (Share Buyback Authorization)

Proposal: Authorize the Company and/or subsidiaries to make market purchases of Company shares.
Votes For: 553,051,315
Votes Against: 1,647,206
Abstain: 1,691,544
Status: Approved

Important for Investors: This proposal gives the Company flexibility to buy back shares from the open market. Share buybacks can reduce share count, support the share price, and signal management’s confidence in the Company’s valuation. This is a potentially price sensitive item.

3. Setting Treasury Share Re-allotment Price Range

Proposal: Determine the price range at which the Company can re-allot shares that it holds as treasury shares.
Votes For: 553,600,547
Votes Against: 1,799,690
Abstain: 1,789,517
Status: Approved

This gives the Board flexibility to re-issue shares from treasury at market-appropriate prices, potentially impacting supply and dilution. This is a material authorization for capital management.

4. Non-Binding Advisory Vote on Executive Compensation (“Say on Pay”)

Proposal: Advisory vote on executive compensation.
Votes For: 486,785,469
Votes Against: 31,871,518
Abstain: 1,295,508
Broker Non-Votes: 36,437,570
Status: Approved

While advisory, this measure reflects ongoing shareholder support for management’s pay structure. A significant “Against” vote would have been a negative signal, but the approval suggests alignment between management and shareholders.

5. Authority to Allot Shares up to 20% of Issued Capital

Proposal: Approve the Board’s authority to allot shares up to an aggregate nominal value of US\$1,286,103 (approx. 20% of issued share capital).
Status: Approved

Price-Sensitive Note: This is a significant authorization and could lead to equity issuance or capital raises in the future, which could result in dilution for existing shareholders. Investors should monitor for any future announcements regarding share issuance under this authority.

6. Waiver of Pre-Emption Rights on Cash Issuance of Shares (Up to 20% of Capital)

Proposal: Waive shareholders’ statutory pre-emption rights in the event of a cash issuance of ordinary shares, limited to 20% of issued share capital.
Status: Approved

Crucial for Investors: This gives the Board flexibility to issue new shares for cash without first offering them to existing shareholders. This could impact share price if exercised, as it may result in dilution. Investors should closely watch for any capital raising announcements.

Other Information

  • Emerging Growth Company Status: The Company confirmed it is not an “emerging growth company.”
  • Trading Symbols: The Company’s ordinary shares trade on NYSE under the symbol “JCI”. Multiple series of senior notes are also listed under various symbols (e.g., JCI27, JCI28, JCI29, etc.).
  • No Amendments: The filing is not an amendment of a previous filing.

Conclusion

All proposals were approved with strong shareholder support. The Board now has significant authority for capital management, including share buybacks, re-issuance of treasury shares, and the ability to issue new shares up to 20% of share capital without pre-emption rights. These authorizations are potentially price-sensitive and could impact the share price depending on how and when they are exercised.

Investors should monitor future Company announcements regarding share buybacks, capital raises, or other changes to share structure. The results of this AGM provide flexibility to management, which could be used for strategic initiatives, but also carry the risk of dilution if new shares are issued.


Disclaimer: The above article is a summary and interpretation of official SEC filings and AGM vote results from Johnson Controls International PLC. It is provided for informational purposes only and does not constitute investment advice. Investors should review the full, official filings and consult with their financial advisors before making investment decisions.




View Johnson Controls International plc Historical chart here



JEWETT-CAMERON TRADING COMPANY LTD. 8-K SEC Filing Summary – NASDAQ, Common Stock, Corporate Details & Compliance 3435

Jewett-Cameron Trading Company Ltd. Announces Results of Annual General Meeting Jewett-Cameron Trading Company Ltd. Announces Results of Annual General Meeting North Plains, OR – Jewett-Cameron Trading Company Ltd. (NASDAQ: JCTC) has released the results...

Brighthouse Financial Reports Q4 and Full Year 2025 Earnings Results and Financial Supplement

Brighthouse Financial, Inc. Reports Q4 and Full-Year 2025 Results Brighthouse Financial, Inc. Announces Fourth Quarter and Full-Year 2025 Earnings Brighthouse Financial, Inc. (Nasdaq: BHF), a major provider of annuities and life insurance, released its...

United Therapeutics’ Ralinepag Achieves 55% Reduction in Clinical Worsening for Pulmonary Arterial Hypertension in Pivotal Phase 3 Trial

United Therapeutics Reports Landmark Phase 3 Results for Ralinepag in PAH United Therapeutics Reports Landmark Phase 3 Results for Ralinepag in Pulmonary Arterial Hypertension Key Highlights Ralinepag Achieves 55% Risk Reduction in Clinical Worsening...

   Ad